Illumina Posts Modest Q2 Revenue Growth Amidst Stable Operations
Ticker: ILMN · Form: 10-Q · Filed: Aug 1, 2025 · CIK: 1110803
| Field | Detail |
|---|---|
| Company | Illumina, INC. (ILMN) |
| Form Type | 10-Q |
| Filed Date | Aug 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Genomics, Biotechnology, Life Sciences, Sequencing Technology, Q2 Earnings, Revenue Growth, SEC Filing
TL;DR
**ILMN is showing steady growth, making it a solid long-term hold in the genomics space.**
AI Summary
ILLUMINA, INC. reported product revenue of $1.05 billion for the three months ended June 29, 2025, compared to $1.02 billion for the same period in 2024, representing a 2.9% increase. Service revenue also saw growth, reaching $250 million for the three months ended June 29, 2025, up from $230 million in the prior year, an 8.7% increase. Total revenue for the second quarter of 2025 was $1.30 billion, a 3.2% increase from $1.25 billion in the second quarter of 2024. The company's retained earnings increased from $4.5 billion as of December 31, 2023, to $4.7 billion as of June 29, 2025, indicating profitability. There were no significant changes in business operations or major new risks disclosed beyond ongoing litigation and market competition. The strategic outlook remains focused on expanding its genomics sequencing technology, as evidenced by consistent product and service revenue growth. The company continues to manage its capital structure, with common stock remaining stable at $1 million and additional paid-in capital at $10.5 billion as of June 29, 2025.
Why It Matters
Illumina's steady revenue growth of 3.2% year-over-year for Q2 2025, driven by both product and service segments, signals resilience in a competitive genomics market. For investors, this indicates consistent demand for its sequencing technology, potentially stabilizing stock performance. Employees benefit from a stable company with continued investment in its core business. Customers can expect ongoing innovation and support for Illumina's platforms, reinforcing its market leadership against rivals like Pacific Biosciences. The broader market sees a key player in the life sciences maintaining its trajectory, which can influence sector-wide sentiment and investment.
Risk Assessment
Risk Level: medium — The risk level is medium due to ongoing competitive pressures in the genomics market and potential impacts from litigation, though the filing doesn't detail specific new legal threats. While revenue is growing, the pace is modest at 3.2% year-over-year, suggesting that significant market share gains might be challenging. The company's consistent financial performance, with retained earnings increasing from $4.5 billion to $4.7 billion, provides a buffer against these risks.
Analyst Insight
Investors should consider holding ILMN, given its consistent revenue growth in both product and service segments. Monitor future filings for any significant developments in competitive landscape or litigation that could impact its market position. The stable financial health suggests a reliable, albeit not rapidly accelerating, investment.
Financial Highlights
- revenue
- $1.30B
- revenue Growth
- +3.2%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $1.05B | +2.9% |
| Service Revenue | $250M | +8.7% |
Key Numbers
- $1.30B — Total Revenue Q2 2025 (Increased 3.2% from $1.25 billion in Q2 2024)
- $1.05B — Product Revenue Q2 2025 (Increased 2.9% from $1.02 billion in Q2 2024)
- $250M — Service Revenue Q2 2025 (Increased 8.7% from $230 million in Q2 2024)
- 3.2% — Total Revenue Growth (Year-over-year growth for Q2 2025)
- $4.7B — Retained Earnings (As of June 29, 2025, up from $4.5 billion at year-end 2023)
Key Players & Entities
- ILLUMINA, INC. (company) — filer of the 10-Q
- $1.05 billion (dollar_amount) — product revenue for Q2 2025
- $1.02 billion (dollar_amount) — product revenue for Q2 2024
- $250 million (dollar_amount) — service revenue for Q2 2025
- $230 million (dollar_amount) — service revenue for Q2 2024
- $1.30 billion (dollar_amount) — total revenue for Q2 2025
- $1.25 billion (dollar_amount) — total revenue for Q2 2024
- $4.7 billion (dollar_amount) — retained earnings as of June 29, 2025
- $4.5 billion (dollar_amount) — retained earnings as of December 31, 2023
- Pacific Biosciences (company) — competitor in the genomics market
FAQ
What were Illumina's total revenues for the second quarter of 2025?
Illumina's total revenues for the second quarter ended June 29, 2025, were $1.30 billion, representing a 3.2% increase from $1.25 billion in the second quarter of 2024.
How did Illumina's product revenue perform in Q2 2025 compared to Q2 2024?
Illumina's product revenue for the three months ended June 29, 2025, was $1.05 billion, an increase of 2.9% from $1.02 billion reported for the same period in 2024.
What was the change in Illumina's service revenue for the second quarter?
Illumina's service revenue increased to $250 million for the three months ended June 29, 2025, up 8.7% from $230 million in the corresponding period of 2024.
What is the current status of Illumina's retained earnings?
As of June 29, 2025, Illumina's retained earnings stood at $4.7 billion, showing an increase from $4.5 billion as of December 31, 2023.
Are there any new significant risks mentioned in Illumina's latest 10-Q filing?
The 10-Q filing for Illumina does not disclose any new significant risks beyond ongoing competitive pressures and general litigation, which are typical for a company in its industry.
How does Illumina's Q2 2025 performance impact its competitive position?
Illumina's consistent 3.2% revenue growth in Q2 2025, driven by both product and service segments, indicates a stable market position and continued demand for its genomics sequencing technology, reinforcing its competitive standing.
What should investors know about Illumina's capital structure from this filing?
Investors should note that Illumina's common stock remained stable at $1 million and additional paid-in capital at $10.5 billion as of June 29, 2025, indicating a consistent capital structure.
What is Illumina's fiscal year end?
Illumina's fiscal year ends on December 28, as indicated in the filing data.
Where is Illumina's business headquarters located?
Illumina's business headquarters is located at 5200 Illumina Way, San Diego, CA 92122.
What was the total revenue for Illumina for the six months ended June 29, 2025?
The filing indicates total revenue for the six months ended June 29, 2025, was $2.55 billion, compared to $2.45 billion for the six months ended June 30, 2024.
Risk Factors
- Ongoing Litigation [medium — legal]: The company is involved in ongoing litigation, which presents potential financial and reputational risks. Specific details and potential financial impact are not quantified in this filing.
- Market Competition [medium — market]: Illumina faces significant competition within the genomics sequencing market. This competition could impact market share and pricing power, although specific competitive pressures are not detailed.
Industry Context
Illumina operates in the laboratory analytical instruments sector, specifically focusing on genomics sequencing technology. The industry is characterized by rapid technological advancements and significant R&D investment. Key competitors vie for market share through innovation and expanding applications of genomic analysis.
Regulatory Implications
As a publicly traded company, Illumina is subject to SEC regulations and reporting requirements, including the timely filing of 10-Q reports. Ongoing litigation also presents potential regulatory scrutiny or legal compliance challenges.
What Investors Should Do
- Monitor litigation updates
- Analyze drivers of service revenue growth
- Assess competitive landscape
Key Dates
- 2025-06-29: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing revenue and financial position.
- 2025-08-01: Filing Date of 10-Q — Indicates the official release of the company's financial performance for the period ending June 29, 2025.
- 2024-06-30: End of Second Quarter 2024 — Comparative period for revenue growth analysis.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the primary source of the financial data and operational updates for Illumina, Inc.)
- Retained Earnings
- The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (An increase in retained earnings from $4.5 billion to $4.7 billion indicates consistent profitability for Illumina, Inc.)
- Additional Paid-In Capital
- The amount of capital a company has received from investors in exchange for stock, above the stock's par value. (Shows the stability of the company's equity structure, remaining at $10.5 billion.)
Year-Over-Year Comparison
Total revenue for Q2 2025 increased by 3.2% to $1.30 billion, compared to $1.25 billion in Q2 2024. Product revenue saw a 2.9% increase, while service revenue demonstrated stronger growth at 8.7%. Retained earnings have grown to $4.7 billion as of June 29, 2025, up from $4.5 billion at the end of 2023, indicating continued profitability. No new significant risks beyond existing litigation and market competition were disclosed.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 1, 2025 regarding ILLUMINA, INC. (ILMN).